Abstract
These are exciting times for bioinformaticians, computational biologists and drug designers with the genome and proteome sequences and related structural databases growing at an accelerated pace. The post-genomic era has triggered high expectations for a rapid and successful treatment of diseases. However, in this biological information rich and functional knowledge poor scenario, the challenges are indeed grand, no less than the assembly of the genome of the whole organism. These include functional annotation of genes, identification of druggable targets, prediction of three-dimensional structures of protein targets from their amino acid sequences, arriving at lead compounds for these targets followed by a transition from bench to bedside. We propose here a “Genome to Hits In Silico” strategy (called Dhanvantari) and illustrate it on Chikungunya virus (CHIKV). “Genome to hits” is a novel pathway incorporating a series of steps such as gene prediction, protein tertiary structure determination, active site identification, hit molecule generation, docking and scoring of hits to arrive at lead compounds. The current state of the art for each of the steps in the pathway is high-lighted and the feasibility of creating an automated genome to hits assembly line is discussed.
Keywords: Genome annotation, protein folding, docking and scoring, lead molecule, CHIKV.
Current Pharmaceutical Design
Title:Genomes to Hits In Silico - A Country Path Today, A Highway Tomorrow: A Case Study of Chikungunya
Volume: 19 Issue: 26
Author(s): Anjali Soni, Khushhali M. Pandey, Pratima Ray and B. Jayaram
Affiliation:
Keywords: Genome annotation, protein folding, docking and scoring, lead molecule, CHIKV.
Abstract: These are exciting times for bioinformaticians, computational biologists and drug designers with the genome and proteome sequences and related structural databases growing at an accelerated pace. The post-genomic era has triggered high expectations for a rapid and successful treatment of diseases. However, in this biological information rich and functional knowledge poor scenario, the challenges are indeed grand, no less than the assembly of the genome of the whole organism. These include functional annotation of genes, identification of druggable targets, prediction of three-dimensional structures of protein targets from their amino acid sequences, arriving at lead compounds for these targets followed by a transition from bench to bedside. We propose here a “Genome to Hits In Silico” strategy (called Dhanvantari) and illustrate it on Chikungunya virus (CHIKV). “Genome to hits” is a novel pathway incorporating a series of steps such as gene prediction, protein tertiary structure determination, active site identification, hit molecule generation, docking and scoring of hits to arrive at lead compounds. The current state of the art for each of the steps in the pathway is high-lighted and the feasibility of creating an automated genome to hits assembly line is discussed.
Export Options
About this article
Cite this article as:
Soni Anjali, Pandey M. Khushhali, Ray Pratima and Jayaram B., Genomes to Hits In Silico - A Country Path Today, A Highway Tomorrow: A Case Study of Chikungunya, Current Pharmaceutical Design 2013; 19 (26) . https://dx.doi.org/10.2174/13816128113199990379
DOI https://dx.doi.org/10.2174/13816128113199990379 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vascular Wall-Related Biomarkers in Sepsis: A Review of Current Evidence and a Critical Appraisal of Recent Patents
Recent Patents on Biomarkers Interleukin-15 in Gene Therapy of Cancer
Current Gene Therapy Cow’s Milk Allergy in Children, from Avoidance to Tolerance
Endocrine, Metabolic & Immune Disorders - Drug Targets Hangover Research Needs: Proceedings of the 5th Alcohol Hangover Research Group Meeting
Current Drug Abuse Reviews Implications for Endothelium-Derived Hyperpolarizing Factor (EDHF) in Womens Cardiovascular Health
Current Women`s Health Reviews The Impact of Human Allelic Variation on HIV-1 Disease
Current HIV Research Invasive Aspergillosis in Children and Adolescents
Current Pharmaceutical Design A New Twist in Cellular Resistance to the Anticancer Drug Bleomycin-A5
Current Drug Metabolism Interferon-γ , Pulmonary Macrophages and Airway Responsiveness in Asthma
Inflammation & Allergy - Drug Targets (Discontinued) The “Aged Garlic Extract” (AGE) and One of its Active Ingredients S-Allyl-LCysteine (SAC) as Potential Preventive and Therapeutic Agents for Alzheimer's Disease (AD)
Current Medicinal Chemistry Recombinant Human Polyclonal Antibodies: A New Class of Therapeutic Antibodies Against Viral Infections
Current Pharmaceutical Design Antibiotic Susceptibility and Treatment of Brucellosis
Recent Patents on Anti-Infective Drug Discovery Nanodrug Delivery Systems in Dentistry: A Review on Current Status and Future Perspectives
Current Drug Delivery The Role of Arthroscopy in Wrist Arthritis
Current Rheumatology Reviews Medicinal Properties of Neem Leaves: A Review
Current Medicinal Chemistry - Anti-Cancer Agents Hyaluronidase Inhibitors: A Biological and Therapeutic Perspective
Current Medicinal Chemistry Diclofenac 1,3,4-Oxadiazole Derivatives; Biology-Oriented Drug Synthesis (BIODS) in Search of Better Non-Steroidal, Non-Acid Antiinflammatory Agents
Medicinal Chemistry Acknowledgment to Reviewers
Recent Patents on Inflammation & Allergy Drug Discovery Models to Predict Intestinal Absorption of Therapeutic Peptides and Proteins
Current Drug Metabolism Antihistamines as Important Tools for Regulating Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents